Activation of STAT5 contributes to proliferation in U87 human glioblastoma multiforme cells

Cui Feng1, Shouqiang Cao2

  • 1Department of Anesthesiology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.

Insights

Hepatocyte growth factor (HGF) activates signal transducers and activators of transcription 5 (STAT5) in glioblastoma cells, promoting proliferation. Inhibiting STAT5 significantly suppressed tumor growth, suggesting it as a therapeutic target for glioblastoma.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Signaling

Background:

  • Signal transducers and activators of transcription 5 (STAT5) phosphorylation is induced by growth factors, but its role in glioblastoma (GBM) proliferation and nuclear translocation is not fully understood.
  • Glioblastoma multiforme (GBM) is an aggressive brain tumor with limited treatment options.

Purpose of the Study:

  • To investigate the role of STAT5 in human glioblastoma cell proliferation.
  • To determine the effect of hepatocyte growth factor (HGF) on STAT5 activation and nuclear translocation in GBM cells.
  • To evaluate STAT5 expression in glioma tissues of varying grades.

Main Methods:

  • Utilized U87-MG glioblastoma cell line for in vitro studies.
  • Stimulated cells with HGF and assessed STAT5 phosphorylation and nuclear translocation.
  • Employed RNA interference (siRNA) to knockdown STAT5 expression.
  • Conducted immunohistochemistry (IHC) on glioma and non-neoplastic brain tissues.

Main Results:

  • HGF stimulation induced STAT5 phosphorylation at Tyr-694/699 and its time-dependent nuclear translocation in U87-MG cells.
  • HGF treatment increased U87-MG cell proliferation.
  • STAT5 knockdown via siRNA significantly suppressed glioblastoma cell proliferation, with or without HGF.
  • p-STAT5 expression positively correlated with the histopathological grade of glioma, and was absent in normal brain tissue.

Conclusions:

  • STAT5 activation by HGF drives glioblastoma cell proliferation.
  • STAT5 is a critical mediator of GBM cell growth.
  • Targeting the STAT5 pathway represents a potential therapeutic strategy for glioblastoma.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Tumor Progression02:07

Tumor Progression

3.1K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

2.0K